Latest and emerging therapies for primary biliary cirrhosis and primary sclerosing cholangitis

Claudia O. Zein, Keith Lindor

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) are the two most common causes of chronic cholestatic liver disease in adults. In PBC, therapy with ursodeoxycholic acid (UDCA) is safe and has been associated with tangible biochemical, histologic, and survival benefits. However, a need for different or adjuvant therapies remains for specific subsets of PBC patients, including those who do not respond to UDCA and those who have advanced histologic disease at presentation. Similarly, beneficial therapies for disease-related symptoms that do not typically respond to UDCA (eg, fatigue and pruritus) are still needed. In contrast to PBC, no medical therapy of proven benefit has been identified for patients with PSC. In PBC and PSC, adequate management of complications of chronic cholestasis is important. For both diseases, liver transplantation is the only curative option.

Original languageEnglish (US)
Pages (from-to)13-22
Number of pages10
JournalCurrent Gastroenterology Reports
Volume12
Issue number1
DOIs
StatePublished - Feb 2010
Externally publishedYes

Fingerprint

Sclerosing Cholangitis
Biliary Liver Cirrhosis
Ursodeoxycholic Acid
Therapeutics
Cholestasis
Pruritus
Liver Transplantation
Fatigue
Liver Diseases
Survival

Keywords

  • Primary biliary cirrhosis
  • Primary sclerosing cholangitis
  • Therapy

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Latest and emerging therapies for primary biliary cirrhosis and primary sclerosing cholangitis. / Zein, Claudia O.; Lindor, Keith.

In: Current Gastroenterology Reports, Vol. 12, No. 1, 02.2010, p. 13-22.

Research output: Contribution to journalArticle

@article{1180a5f726ed474e8b989f0199f9ba84,
title = "Latest and emerging therapies for primary biliary cirrhosis and primary sclerosing cholangitis",
abstract = "Primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) are the two most common causes of chronic cholestatic liver disease in adults. In PBC, therapy with ursodeoxycholic acid (UDCA) is safe and has been associated with tangible biochemical, histologic, and survival benefits. However, a need for different or adjuvant therapies remains for specific subsets of PBC patients, including those who do not respond to UDCA and those who have advanced histologic disease at presentation. Similarly, beneficial therapies for disease-related symptoms that do not typically respond to UDCA (eg, fatigue and pruritus) are still needed. In contrast to PBC, no medical therapy of proven benefit has been identified for patients with PSC. In PBC and PSC, adequate management of complications of chronic cholestasis is important. For both diseases, liver transplantation is the only curative option.",
keywords = "Primary biliary cirrhosis, Primary sclerosing cholangitis, Therapy",
author = "Zein, {Claudia O.} and Keith Lindor",
year = "2010",
month = "2",
doi = "10.1007/s11894-009-0079-2",
language = "English (US)",
volume = "12",
pages = "13--22",
journal = "Current Gastroenterology Reports",
issn = "1522-8037",
publisher = "Current Medicine Group",
number = "1",

}

TY - JOUR

T1 - Latest and emerging therapies for primary biliary cirrhosis and primary sclerosing cholangitis

AU - Zein, Claudia O.

AU - Lindor, Keith

PY - 2010/2

Y1 - 2010/2

N2 - Primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) are the two most common causes of chronic cholestatic liver disease in adults. In PBC, therapy with ursodeoxycholic acid (UDCA) is safe and has been associated with tangible biochemical, histologic, and survival benefits. However, a need for different or adjuvant therapies remains for specific subsets of PBC patients, including those who do not respond to UDCA and those who have advanced histologic disease at presentation. Similarly, beneficial therapies for disease-related symptoms that do not typically respond to UDCA (eg, fatigue and pruritus) are still needed. In contrast to PBC, no medical therapy of proven benefit has been identified for patients with PSC. In PBC and PSC, adequate management of complications of chronic cholestasis is important. For both diseases, liver transplantation is the only curative option.

AB - Primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) are the two most common causes of chronic cholestatic liver disease in adults. In PBC, therapy with ursodeoxycholic acid (UDCA) is safe and has been associated with tangible biochemical, histologic, and survival benefits. However, a need for different or adjuvant therapies remains for specific subsets of PBC patients, including those who do not respond to UDCA and those who have advanced histologic disease at presentation. Similarly, beneficial therapies for disease-related symptoms that do not typically respond to UDCA (eg, fatigue and pruritus) are still needed. In contrast to PBC, no medical therapy of proven benefit has been identified for patients with PSC. In PBC and PSC, adequate management of complications of chronic cholestasis is important. For both diseases, liver transplantation is the only curative option.

KW - Primary biliary cirrhosis

KW - Primary sclerosing cholangitis

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=77950863027&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950863027&partnerID=8YFLogxK

U2 - 10.1007/s11894-009-0079-2

DO - 10.1007/s11894-009-0079-2

M3 - Article

C2 - 20425480

AN - SCOPUS:77950863027

VL - 12

SP - 13

EP - 22

JO - Current Gastroenterology Reports

JF - Current Gastroenterology Reports

SN - 1522-8037

IS - 1

ER -